MapLight Therapeutics, Inc.
MPLT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$323.05M
Close$
$0.93
86.1% downside
Current Fair Value
86.1% downsideOvervalued by 86.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $323.05 Million |
|---|---|
| Enterprise Value | $253.40 Million |
| Earnings per Share | $-3.66 |
| Beta | 2.77 |
| Outstanding Shares | 45,431,359 |
Return
| Return on Equity | -65.99% |
|---|---|
| Return on Assets | -62.39% |
| Return on Invested Capital | -69.60% |
Valuation & Multiples
| P/E Ratio | -1.46 |
|---|---|
| PEG | -1.44 |
| Price to Sales | - |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.04 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-1.35
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 3, 2026
EPS Estimate
$-1.22
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 58.29% |
|---|---|
| Total Invested | $15,315▼ 100.00% |
| Investors Holding | 2▼ 108.00% |
About MapLight Therapeutics, Inc.
109 employees
CEO: Christopher A. Kroeger
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /...